Leerink Partnrs Issues Negative Estimate for KROS Earnings

Key Points

• Leerink Partners has revised down its Q3 2025 earnings estimate for Keros Therapeutics, projecting an earning of ($0.87) per share, down from ($0.82).
• The consensus estimate for Keros Therapeutics' full-year earnings stands at ($4.74) per share, with several analysts adjusting their price targets for the stock.
• Keros Therapeutics reported a quarterly EPS of ($0.76), which surpassed the consensus estimate of ($1.14).

Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Investment analysts at Leerink Partnrs dropped their Q3 2025 earnings per share (EPS) estimates for Keros Therapeutics in a research note issued to investors on Thursday, August 7th. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnings per share of ($0.87) for the quarter, down from their prior estimate of ($0.82). The consensus estimate for Keros Therapeutics' current full-year earnings is ($4.74) per share. Leerink Partnrs also issued estimates for Keros Therapeutics' Q4 2025 earnings at ($0.78) EPS, FY2025 earnings at $1.25 EPS, FY2026 earnings at ($4.26) EPS, FY2027 earnings at ($3.41) EPS, FY2028 earnings at ($1.08) EPS and FY2029 earnings at ($1.59) EPS.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.76) EPS for the quarter, topping analysts' consensus estimates of ($1.14) by $0.38. The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $3.83 million. Keros Therapeutics had a return on equity of 2.96% and a net margin of 8.06%. The company's revenue was up 49002.7% on a year-over-year basis. During the same period last year, the company earned ($1.25) earnings per share.

Several other equities research analysts have also recently commented on the company. Wedbush restated a "neutral" rating and issued a $15.00 target price on shares of Keros Therapeutics in a research note on Friday, May 30th. Bank of America lowered Keros Therapeutics from a "buy" rating to a "neutral" rating and decreased their price objective for the company from $32.00 to $18.00 in a report on Tuesday, June 10th. Scotiabank cut their target price on Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating for the company in a research report on Monday, May 12th. Finally, HC Wainwright cut their target price on Keros Therapeutics from $25.00 to $20.00 and set a "buy" rating for the company in a research report on Friday. Seven research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $30.00.

Keros Therapeutics Price Performance

Shares of Keros Therapeutics stock traded up $0.36 during trading on Monday, hitting $13.71. 305,989 shares of the company were exchanged, compared to its average volume of 999,934. Keros Therapeutics has a 1-year low of $9.12 and a 1-year high of $72.37. The firm has a market capitalization of $556.90 million, a P/E ratio of 44.23, a price-to-earnings-growth ratio of 1.80 and a beta of 1.33. The firm's fifty day moving average price is $14.00 and its 200 day moving average price is $12.81.

Institutional Investors Weigh In On Keros Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in KROS. FNY Investment Advisers LLC acquired a new stake in shares of Keros Therapeutics in the first quarter valued at about $25,000. CWM LLC grew its stake in Keros Therapeutics by 10,157.7% during the first quarter. CWM LLC now owns 2,667 shares of the company's stock worth $27,000 after purchasing an additional 2,641 shares during the period. Virtus ETF Advisers LLC grew its stake in Keros Therapeutics by 107.5% during the fourth quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company's stock worth $61,000 after purchasing an additional 1,998 shares during the period. Police & Firemen s Retirement System of New Jersey grew its stake in Keros Therapeutics by 29.7% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 8,257 shares of the company's stock worth $110,000 after purchasing an additional 1,892 shares during the period. Finally, CANADA LIFE ASSURANCE Co grew its stake in Keros Therapeutics by 207.8% during the fourth quarter. CANADA LIFE ASSURANCE Co now owns 7,371 shares of the company's stock worth $116,000 after purchasing an additional 4,976 shares during the period. Institutional investors and hedge funds own 71.56% of the company's stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.